LONDON - Anglo/German kinase specialist Cellzome Inc., sealed a deal worth a headline value of £830 million (US$1.5 billion) with GlaxoSmithKline plc for the development of kinase inhibitors in the treatment of inflammatory diseases. (BioWorld Today) Read More
